Trial Profile

A phase 1 clinical study of BHV-1400 for the treatment of IgA nephropathy

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 03 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs BHV 1400 (Primary)
Indications IgA nephropathy
Focus Therapeutic Use

Most Recent Events

28 May 2025 Results presented in a Biohaven Pharmaceutical Holding Company Media Release.
03 Mar 2025 According to Biohaven Therapeutics media release, this study is expected to be completed in 1H 2025.
13 Jan 2025 According to Biohaven Therapeutics media release, data from the study will be presented at the 43rd Annual J.P. Morgan Healthcare Conference,

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com